Physician profile
Ross Davis
NPI 1033512140
$6,575.48
in general payments reported to CMS, 2019-2025
23 companies · $3,066 in 2025
The $3,066 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,209 · 2022: $715 · 2023: $1,091 · 2024: $496 · 2025: $3,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,543 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,543.46 |
| Education | $108.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,325.08 | 2021-2025 | |
| Ucb, INC. | $758.02 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $559.41 | 2024-2025 | |
| Genzyme Corporation | $496.83 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $488.74 | 2021-2025 | Dupixent |
| Janssen Biotech, INC. | $483.50 | 2021-2023 | Tremfya |
| Incyte Corporation | $472.69 | 2024-2025 | Opzelura |
| Pfizer INC. | $409.45 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $258.58 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $231.49 | 2021-2025 | |
| Galderma Laboratories, L.P. | $229.52 | 2021-2025 | Nemluvio, Aklief, Epsolay |
| Allergan, INC. | $215.32 | 2021-2022 | |
| Amgen INC. | $158.37 | 2021-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $119.65 | 2021-2025 | |
| Almirall LLC | $83.51 | 2021-2023 | Seysara |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $63.10 | 2025 | Vtama |
| Journey Medical Corporation | $48.84 | 2022-2025 | |
| Leo Pharma INC. | $35.70 | 2021-2022 | |
| Dermira, INC. | $35.52 | 2021 | |
| Lilly USA, LLC | $27.73 | 2023 | Olumiant |
| Dermavant Sciences, INC. | $27.03 | 2023 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $25.98 | 2023 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.42 | 2024 | Arazlo, Cabtreo, Jublia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.